Arcutis Biotherapeutics
ARQT
26.36
-0.81
-2.98%
Arcutis Biotherapeutics
US · ARQT
#2465 by market cap
Listed 2020
26.36
-0.81
-2.98%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36Market Newswire · 2026/7/1
-
Rating change
Cantor Fitzgerald Initiates Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $48Market Newswire · 2026/10/15
-
Rating change
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $35Market Newswire · 2026/2/28
-
Morgan Stanley Initiates Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $38Market Newswire · 2026/11/5
-
Rating change
Goldman Sachs Maintains Arcutis Biotherapeutics(ARQT.US) With Hold Rating, Raises Target Price to $33Market Newswire · 2026/2/27
-
Rating change
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/7/15
-
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/11/5
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)TipRanks · 2026/5/26
-
Rating change
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36Market Newswire · 2026/5/8
-
Rating change
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/8/11
-
Rating change
Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/5/26
-
Rating change
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $40Market Newswire · 2026/8/7
-
Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q3 Revenue $143.9M, Vs. FactSet Est of $142.6MMT Newswires · 2026/11/5
-
Rating change
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/4/22
-
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/11/5
-
Rating change
Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $35Market Newswire · 2026/2/27
-
Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $44Market Newswire · 2026/10/19
-
Rating change
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)TipRanks · 2026/8/11
-
Rating change
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)TipRanks · 2026/4/22
-
Rating change
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/4/23
-
Rating change
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37Market Newswire · 2026/2/27
-
Rating change
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/1/29
-
Form 144 | Arcutis Biotherapeutics(ARQT.US) Insider Proposes to Sell 8.55 Million in Common StocksMarket Newswire · 2026/9/17
-
Rating change
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/2/3
-
Rating change
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $37Market Newswire · 2026/1/27
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Arcutis Biotherapeutics discussion 0 comments